These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 26616595)

  • 1. Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin.
    Kim YA; Yoo WS; Hong ES; Ku EJ; Park KS; Lim S; Cho YM; Park KS; Jang HC; Choi SH
    Diabetes Metab J; 2015 Dec; 39(6):489-97. PubMed ID: 26616595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.
    Göke R; Gruenberger JB; Bader G; Dworak M
    Curr Med Res Opin; 2014 May; 30(5):785-9. PubMed ID: 24328429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination Therapy with a Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Metformin Markedly Improves HbA1c Levels in Japanese Patients with Type 2 Diabetes Mellitus.
    Hirao K; Maeda H; Shirabe S; Yamamoto R; Hirao T; Hirao S; Yamauchi M; Arai K
    Jpn Clin Med; 2012; 3():1-7. PubMed ID: 23946679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Effectiveness of Adding Alogliptin to Metformin Plus Sulfonylurea with Other DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.
    Kay S; Strickson A; Puelles J; Selby R; Benson E; Tolley K
    Diabetes Ther; 2017 Apr; 8(2):251-273. PubMed ID: 28275958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.
    Fass AD; Gershman JA
    Adv Ther; 2013 Apr; 30(4):337-53. PubMed ID: 23605247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipeptidyl peptidase-IV inhibitors are efficient adjunct therapy in HNF1A maturity-onset diabetes of the young patients--report of two cases.
    Katra B; Klupa T; Skupien J; Szopa M; Nowak N; Borowiec M; Kozek E; Malecki MT
    Diabetes Technol Ther; 2010 Apr; 12(4):313-6. PubMed ID: 20210571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of HbA
    Tan WY; Hsu W; Lee ML; Tan NC
    Sci Rep; 2023 Nov; 13(1):20891. PubMed ID: 38017086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complementing insulin therapy to achieve glycemic control.
    Barnett AH
    Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study.
    Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
    Diabetes Obes Metab; 2014 Oct; 16(10):1001-8. PubMed ID: 24827939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Efficacy of Quadruple Oral Therapy for Type 2 Diabetes in Real-World Practice: A Retrospective Observational Study.
    Cho YK; Lee J; Kim HS; Park JY; Jung CH; Lee WJ
    Diabetes Ther; 2020 Sep; 11(9):2029-2039. PubMed ID: 32696268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
    Guthrie RM
    Postgrad Med; 2015 Jun; 127(5):463-79. PubMed ID: 25956345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidyl peptidase-4 inhibitors have protective effect on cognitive impairment in aged diabetic patients with mild cognitive impairment.
    Rizzo MR; Barbieri M; Boccardi V; Angellotti E; Marfella R; Paolisso G
    J Gerontol A Biol Sci Med Sci; 2014 Sep; 69(9):1122-31. PubMed ID: 24671867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: A 12-Week Interim Report.
    Kim HJ; Kim YS; Lee CB; Choi MG; Chang HJ; Kim SK; Yu JM; Kim TH; Lee JH; Ahn KJ; Kim K; Lee KW
    Diabetes Ther; 2019 Aug; 10(4):1271-1282. PubMed ID: 31079357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment adherence with vildagliptin compared to sulphonylurea as add-on to metformin in Muslim patients with type 2 diabetes mellitus fasting during Ramadan.
    Hanif W; Malik W; Hassanein M; Kamal A; Geransar P; Andrews C; Azam M; Barnett AH
    Curr Med Res Opin; 2013 Jul; 29(7):807-11. PubMed ID: 23659561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combination therapy of metformin vs dipeptidulpeptidase inhibitors and sulfonylureas in type 2 diabetes: clinical and economic impact].
    Sicras-Mainar A; Navarro-Artieda R
    Rev Peru Med Exp Salud Publica; 2014; 31(4):626-34. PubMed ID: 25597711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin + saxagliptin for type 2 diabetes.
    Scheen AJ
    Expert Opin Pharmacother; 2012 Jan; 13(1):139-46. PubMed ID: 22149373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.